Advisers will weigh letting pharmacies compound peptides like TB-500, KPV and semax, barred in 2023, after RFK Jr. said he is a fan of peptides.
Recap by typeshit. Full story at Medical Economics.
Kalkine Media ties the attention on Lilly to orforglipron's progress, arguing a pill could scale cheaper than injectables and ease supply limits.
Smaller portions could become more common on shelves, with inflation and GLP-1 appetite changes both pushing food makers toward personal packs.
Chokshi notes the sales were 0.4% of Lilly's $23 billion quarter, and that Divi's Labs hasn't announced any role in making the drug.
Oral Wegovy brought in about $850 million in H1 2026 and holds over 80% of new US oral scripts. Lilly says Foundayo volume doubled in a month.
A thin search result says Lilly has cut the price of its weight loss drug. No figures, dates or product names are included.
The market report credits the rise in sales value to new generics and steady prices, with Eli Lilly's tirzepatide named among the drivers.
Loading…